Gain Therapeutics Inc
NASDAQ:GANX
Gain Therapeutics Inc
NASDAQ:GANX
Price:
1.8
USD
-2.17%
Market Closed
Market Cap:
$69.2m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Gain Therapeutics Inc
NASDAQ:GANX
|
US |
Income Statement
Earnings Waterfall
Gain Therapeutics Inc
Gain Therapeutics Inc
Income Statement
Gain Therapeutics Inc
Gain Therapeutics Inc
Currency: USD
| Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||
| Revenue |
0
N/A
|
0
+30%
|
0
+23%
|
0
+31%
|
0
+5%
|
0
-14%
|
0
-26%
|
0
+14%
|
0
-63%
|
0
N/A
|
0
-8%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | ||||||||||||||||||
| Operating Expenses |
(6)
|
(11)
|
(14)
|
(15)
|
(17)
|
(17)
|
(18)
|
(20)
|
(22)
|
(22)
|
(22)
|
(21)
|
(22)
|
(21)
|
(20)
|
(20)
|
(17)
|
|
| Selling, General & Administrative |
(3)
|
(5)
|
(7)
|
(8)
|
(8)
|
(9)
|
(10)
|
(10)
|
(11)
|
(11)
|
(11)
|
(10)
|
(10)
|
(10)
|
(10)
|
(10)
|
(9)
|
|
| Research & Development |
(3)
|
(6)
|
(7)
|
(7)
|
(8)
|
(8)
|
(8)
|
(10)
|
(11)
|
(11)
|
(11)
|
(11)
|
(12)
|
(12)
|
(11)
|
(10)
|
(9)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
|
| Operating Income |
(6)
N/A
|
(11)
-78%
|
(14)
-30%
|
(15)
-6%
|
(16)
-11%
|
(16)
-1%
|
(18)
-8%
|
(20)
-11%
|
(22)
-13%
|
(22)
-1%
|
(22)
+1%
|
(21)
+4%
|
(22)
-2%
|
(21)
+2%
|
(20)
+5%
|
(20)
+0%
|
(17)
+15%
|
|
| Pre-Tax Income | ||||||||||||||||||
| Interest Income Expense |
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
|
| Pre-Tax Income |
(6)
N/A
|
(11)
-78%
|
(14)
-30%
|
(15)
-6%
|
(16)
-10%
|
(16)
+1%
|
(18)
-8%
|
(19)
-11%
|
(22)
-13%
|
(22)
-1%
|
(22)
-1%
|
(21)
+5%
|
(22)
-2%
|
(21)
+1%
|
(20)
+7%
|
(20)
-2%
|
(18)
+12%
|
|
| Net Income | ||||||||||||||||||
| Tax Provision |
0
|
(0)
|
0
|
0
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
|
| Income from Continuing Operations |
(6)
|
(11)
|
(14)
|
(15)
|
(16)
|
(16)
|
(18)
|
(19)
|
(22)
|
(22)
|
(22)
|
(21)
|
(22)
|
(21)
|
(20)
|
(21)
|
(19)
|
|
| Net Income (Common) |
(6)
N/A
|
(11)
-78%
|
(14)
-30%
|
(15)
-6%
|
(16)
-10%
|
(16)
+1%
|
(18)
-9%
|
(19)
-11%
|
(22)
-13%
|
(22)
-1%
|
(22)
0%
|
(21)
+5%
|
(22)
-2%
|
(21)
+1%
|
(20)
+4%
|
(21)
-3%
|
(19)
+11%
|
|
| EPS (Diluted) |
-0.51
N/A
|
-0.9
-76%
|
-1.37
-52%
|
-1.24
+9%
|
-1.37
-10%
|
-1.36
+1%
|
-1.48
-9%
|
-1.63
-10%
|
-1.78
-9%
|
-1.74
+2%
|
-1.71
+2%
|
-1.17
+32%
|
-1.12
+4%
|
-0.8
+29%
|
-0.89
-11%
|
-0.72
+19%
|
-0.61
+15%
|
|
Switch to:
Switch to:
See Also
Discover More
